First-and second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib, erlotinib, and afatinib) are standard treatments for NSCLC patients with sensitive EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.